Ingredion Incorporated INGR
91.72 USD -5.70 (-5.85%)
At closeNov 6, 2026, 4:25 PM EST
91.72 0.00 0.00%
After hours · Nov 6, 4:25 PM ET
90.19 Day range 94.22
90.19 52-week range 123.49
- YTD
- -16.81%
- 1 year
- -13.84%
Analyst view
Consensus: hold
Hold
Price target (mean) 119.50 +30.3% upside
Now 91.72
- Target (low)
- 104.00
- Target (mean)
- 119.50
- Target (high)
- 150.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.67 | 2.39 – 2.80 | 2.53 | +5.5% | 1.75B | -0.3% | 6 |
| Next quarter | 2.72 | 2.71 – 2.73 | 2.34 | +16.2% | 1.86B | +3.6% | 2 |
| Current year | 10.46 | 10.16 – 10.63 | 11.13 | -6.1% | 7.20B | -0.3% | 7 |
| Next year | 11.23 | 10.80 – 11.84 | 10.46 | +7.4% | 7.35B | +2.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Stephens & Co. | Maintained | Equal-Weight | Equal-Weight |
| Oct 14, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 5, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 5, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 5, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Jun 9, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| May 6, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Apr 22, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Mar 17, 2026 | Benchmark | Initiated | — | Buy |
| Feb 5, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 4, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Feb 4, 2026 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Nov 6, 2025 | Barclays | Downgrade | Overweight | Equal-Weight |
| Nov 5, 2025 | UBS | Maintained | Neutral | Neutral |
| Nov 5, 2025 | Stephens & Co. | Maintained | Equal-Weight | Equal-Weight |
| Nov 5, 2025 | BMO Capital | Maintained | Market Perform | Market Perform |
| Oct 6, 2025 | UBS | Maintained | Neutral | Neutral |
| Jul 9, 2025 | UBS | Maintained | Neutral | Neutral |
| Apr 22, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 7, 2025 | UBS | Downgrade | Buy | Neutral |
| Feb 5, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 5, 2025 | BMO Capital | Maintained | Market Perform | Market Perform |
| Feb 5, 2025 | Stephens & Co. | Maintained | Equal-Weight | Equal-Weight |
| Nov 15, 2024 | UBS | Maintained | Buy | Buy |
| Nov 6, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| Nov 6, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 6, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 21, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 15, 2024 | UBS | Maintained | Buy | Buy |
